Predictors for Severe COVID-19 Infection (original) (raw)
Journal Article
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
,
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
Ascension St John Hospital
, Detroit, Michigan,
USA
Search for other works by this author on:
Editorial decision:
27 May 2020
Corrected and typeset:
24 June 2020
Cite
Ashish Bhargava, Elisa Akagi Fukushima, Miriam Levine, Wei Zhao, Farah Tanveer, Susanna M Szpunar, Louis Saravolatz, Predictors for Severe COVID-19 Infection, Clinical Infectious Diseases, Volume 71, Issue 8, 15 October 2020, Pages 1962–1968, https://doi.org/10.1093/cid/ciaa674
Close
Navbar Search Filter Mobile Enter search term Search
Abstract
Background
COVID-19 is a pandemic disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Predictors for severe COVID-19 infection have not been well defined. Determination of risk factors for severe infection would enable identifying patients who may benefit from aggressive supportive care and early intervention.
Methods
We conducted a retrospective observational study of 197 patients with confirmed COVID-19 admitted to a tertiary academic medical center.
Results
Of 197 hospitalized patients, the mean (SD) age of the cohort was 60.6 (16.2) years, 103 (52.3%) were male, and 156 (82.1%) were black. Severe COVID-19 infection was noted in 74 (37.6%) patients, requiring intubation. Patients aged above 60 were significantly more likely to have severe infection. Patients with severe infection were significantly more likely to have diabetes, renal disease, and chronic pulmonary disease and had significantly higher white blood cell counts, lower lymphocyte counts, and increased C-reactive protein (CRP) than patients with nonsevere infection. In multivariable logistic regression analysis, risk factors for severe infection included pre-existing renal disease (odds ratio [OR], 7.4; 95% CI, 2.5–22.0), oxygen requirement at hospitalization (OR, 2.9; 95% CI, 1.3–6.7), acute renal injury (OR, 2.7; 95% CI, 1.3–5.6), and CRP on admission (OR, 1.006; 95% CI, 1.001–1.01). Race, age, and socioeconomic status were not independent predictors.
Conclusions
Acute or pre-existing renal disease, supplemental oxygen upon hospitalization, and admission CRP were independent predictors for the development of severe COVID-19. Every 1-unit increase in CRP increased the risk of severe disease by 0.06%.
In December 2019, the first pneumonia cases of unknown origin were identified in Wuhan city, Hubei province, China [1]. The pathogen was identified as a novel coronavirus (nCoV), now called severe acute respiratory syndrome coronavirus (SARS-CoV), with the disease termed coronavirus disease 2019 (COVID-19) [2]. Because of its rapid spread, the World Health Organization has declared COVID-19 as a pandemic [3]. As of 28 April 2020, a total of 3 090 844 confirmed cases had been reported in 184 countries [4]. COVID-19 infections have been described among asymptomatic (who never developed symptoms) as well as presymptomatic patients (who are not yet symptomatic) [5–10].
The clinical spectrum from the largest cohort of symptomatic patients with COVID-19 from China ranged from mild to critically ill cases [11]. Age was described as a strong risk factor for severe disease, with the highest case fatalities occurring in those 80 years and older [11–13]. Preliminary data from the United States also suggested that adverse outcomes were most frequent among persons 85 years of age and older, but it was also recognized that severe infections could occur in adults of any age group [14, 15]. Comorbid conditions of hypertension, diabetes, and chronic lung and renal disease were also associated with severe infections and adverse outcomes [16–18]. Medications such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) were suggested to increase the severity of infection [19], but currently there are no data to suggest a link between these medications and adverse outcomes. The determination of risk factors for severity in COVID-19 infection would enable the identification of high-risk patients who may benefit from close monitoring, aggressive supportive care, and early intervention.
To address this question, we collected clinical data from a cohort of hospitalized patients with the aim of identifying predictors for developing severe COVID-19 infections.
METHODS
Study Setting and Design
We conducted a single-center, retrospective observational study at a 776-bed tertiary care urban academic medical center. The study was approved by the Ascension St John Hospital Institutional Review Board. Patients with confirmed COVID-19 (positive real-time reverse transcriptase–polymerase chain reaction [RT-PCR] assay of a nasopharyngeal swab) from 8 March to 8 April 2020 were included. COVID-19 testing for all patients under investigation was done according to criteria defined per the US Centers for Disease Control and Prevention (CDC) [20]. Patients’ nasopharyngeal swab specimens were sent to the Michigan Department of Health and Human Services (MDHHS) Bureau of Laboratories for RT-PCR testing after obtaining an nCoV identification number (ID) from the MDHHS Communicable Disease Division. These nCoV ID numbers were tracked by the institution’s infection-control database. All studied subjects were identified using this database.
Data Collection
Data were collected from the electronic medical record (EMR) for all patients meeting the inclusion criteria. Clinical parameters included age, sex, race, residential zip code plus 4, presence of comorbid conditions (according to the Charlson Comorbidity Index, a validated, weighted index score that predicts mortality), patient’s home medications, vital signs on presentation, presenting symptoms, laboratory and radiological findings on admission, status on intubation and intensive care unit (ICU) admission, and hospital discharge or inpatient death [21]. Clinical outcomes will be addressed in another report.
Definitions
A COVID-19 infection was defined as “severe” if the patient required mechanical ventilation. Obesity and severe obesity were defined according to CDC definitions [22]. Fever was defined as an axillary temperature of 37.5°C or higher. Lymphocytopenia was defined as a lymphocyte count of less than 1500 cells per cubic millimeter. Thrombocytopenia was defined as a platelet count of less than 150 000 per cubic millimeter. Acute renal injury or elevated creatinine on admission was defined as an increase in serum creatinine by 0.3 mg/dL or higher (≥26.5 μmol/L) within 48 hours or an increase in serum creatinine to 1.5 times baseline or higher, which is known or presumed to have occurred within the prior 7 days [23]. Patients with pre-existing renal disease were on dialysis, had a history of renal transplant, had uremic syndrome, or had a creatinine level greater than 3 mg/dL in prior admissions. Using the 9-digit zip code, the area deprivation rank for each individual patient was also obtained. The Area Deprivation Index (ADI) is a measurement of healthcare deprivation based upon where a person lives; it correlates with socioeconomic status [24]. A higher ADI means more deprived. On a national level the ADIs are ranked from 1 to 100 (1 = least deprived, 100 = most deprived) and on a state level the ADIs are ranked from 1 to 10 (1 = least deprived, 10 = most deprived).
Statistical Analysis
Statistical analysis was performed using SPSS version 26.0 (IBM Corporation, Armonk, NY). Descriptive statistics were generated to characterize the study population. Continuous variables were described as the mean with standard deviation (SD) or median with interquartile range (IQR). Univariable analysis was done using Student’s t test, analysis of variance followed by multiple pairwise comparisons using the Bonferroni correction of the P value, the Mann-Whitney U test, and chi-square analysis. Variables that were found to be significant (P < .05) predictors of severity were then entered a multivariable logistic regression model using a forward likelihood ratio algorithm. When 2 variables were measuring the same underlying factor, the variable with the highest univariable measure of association was used in the model. Results from the regression are reported as odds ratios with 95% confidence intervals. All reported P values are 2-sided.
RESULTS
A total of 197 hospitalized patients with confirmed COVID-19 were included in the analysis. The mean (SD) age of the cohort was 60.6 (16.2) years, 103 (52.3%) were male, and 156 (82.1%) were black. The mean body mass index of the cohort was 34.4 (9.0) kg/m2. Of these patients, 161 (84.7%) had at least 1 comorbid condition listed. Hypertension was the most common underlying condition, which was present in 138 (70.1%) patients, followed by diabetes in 73 (37.1%) patients and chronic pulmonary diseases in 38 (19.3%) patients. History of contact with a sick person was present in 60 (31.6%) patients. The mean duration of symptoms prior to hospitalization was 5.4 (3.8) days.
Severe COVID-19 infection was noted in 74 (37.6%) patients, requiring intubation. The median time from hospitalization to intubation was 10.9 hours (IQR: 0.0, 58.2 hours). Time to intubation from the time of hospital admission was less than 2 hours in 22 (29.7%) patients and 2 hours or more in 52 (70.3%) patients. All 74 (100%) intubated patients with severe infection were admitted to the ICU compared with 1 (0.8%) patient among the nonsevere cases. The patients with severe infection tended to be older (mean [SD] age, 63.1 [13.9] vs 59.1 [17.3] years; P = .08) than nonsevere patients. Patients aged 60 years and older were significantly more likely to have severe infection (46 [62.2%] vs 58 [47.2%]; P = .04). Patients with severe infection were more likely to have at least 1 comorbid condition (64 ([91.4%] vs 97 [80.8%]; P = .05) and were significantly more like to have diabetes (36 [48.6%] vs 37 [30.1%]; P = .009), renal disease (22 [29.7%] vs 12 [9.8%]; P < .0001), and chronic pulmonary diseases (20 [27.0%] vs 18 [14.6%]; P = .03). Patients with severe infection were significantly more likely to be tachypneic (mean [SD] breaths/min, 27.6 [10] vs 22.8 [6.6]; P < .0001) and have low oxygen saturation (percentage [SD] 91.4 [9.4] vs 94.7 [4.3]; P = .006) at the time of hospital admission.
There was no significant association found between race and severity of illness (P = .4). To examine this further, we also assessed the association between the median state ADI rank with both race and severity of disease. Although there was a significant association between race and median state ADI rank (white median state rank, 6.0 [IQR, 2.8, 8] vs black median rank, 9.0 [IQR, 7, 9.75]) (P < .0001), there was no association between median state ADI rank and severity of disease.
The most common symptoms at the onset of illness in the studied cohort were cough (141 [73.1%]), shortness of breath (140 [71.1%]), and fever (116 [59.8%]). Among patients with severe disease, 28.4% were confused on presentation compared with 14.6% of those with nonsevere disease (P = .02). History of contact with a sick individual and presence of sore throat and cough were significantly less frequent in patients with severe disease compared with those with nonsevere disease. Patients with severe infection demonstrated an increased inflammatory response, including higher white blood cell counts, lower lymphocyte and platelet counts, and increased C-reactive protein (CRP) levels compared with those patients with nonsevere infection. Although patients with severe infection had significantly elevated procalcitonin levels, which raises concern for the presence of secondary bacterial infection, these patients also had acute renal injury on admission, which may have caused the elevated procalcitonin.
For all demographic data, clinical characteristics, and laboratory findings in univariate analysis shown in Table 1, we identified each variable that showed and/or reached statistical significance with P < .05 between severe and nonsevere infections. For multivariable logistic regression (Table 2), variables initially entered into the model included age, sex, chronic pulmonary disease, renal disease, altered mental status, fever within 24 hours of admission, respiratory rate on admission, oxygenation on admission, cough, shortness of breath, abnormal chest X-ray on admission, initial procalcitonin level, elevated creatinine from baseline, and initial CRP level. After 4 iterations, the model with the lowest −2-log likelihood value included 4 variables that were independent predictors for severity of COVID-19 infection, including presence of pre-existing renal disease, need for supplemental oxygen at the time of hospitalization, and elevated creatinine and CRP on admission laboratory findings.
Table 1.
Univariate Analysis of Predictors for Severe COVID-19 Infection
Characteristics | Nonsevere (n = 123) (%) | Severe (n = 74) (%) | OR (95% CI) | P |
---|---|---|---|---|
Age group | ||||
<60 years | 65 (52.8) | 28 (37.8) | 1.8 (1.02, 3.3) | .04 |
>60 years | 58 (47.2) | 46 (62.2) | … | |
Sex | ||||
Male | 58 (47.2) | 45 (60.8) | 0.6 (.3, 1.03) | .06 |
Female | 65 (52.8) | 29 (39.2) | … | |
Race | ||||
White | 19 (15.8) | 15 (21.4) | 0.7 (.3, 1.5) | .38 |
Black | 101 (84.2) | 55 (78.6) | … | |
Comorbidities | ||||
At least 1 comorbidity | 97 (80.8) | 64 (91.4) | 2.32 (.95, 5.69) | .061 |
Myocardial infarction | 5 (4.1) | 4 (5.4) | 1.34 (.35, 5.19) | .663 |
Congestive heart failure | 10 (8.1) | 10 (13.5) | 1.76 (.70, 4.47) | .226 |
Peripheral vascular disease | 0 (0.0) | 5 (6.8) | … | |
Cerebrovascular disease | 9 (7.3) | 8 10.8) | 1.53 (.57, 4.17) | .398 |
Dementia | 16 (13.0) | 5 (6.8) | .49 (.17, 1.38) | .169 |
Chronic pulmonary disease | 18 (14.6) | 20 (27.0) | 2.16 (1.06, 4.42) | .03 |
Connective tissue disease | 0 (0.0) | 2 (2.7) | … | |
Peptic ulcer disease | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .90 |
Diabetes | 37 (30.1) | 36 (48.6) | 2.20 (1.21, 4.0) | .009 |
Hemiplegia | 5 (4.1) | 4 (5.4) | 1.35 (.35, 5.19) | .66 |
Renal disease | 12 (9.8) | 22 (29.7) | 3.91 (1.80, 8.51) | <.0001 |
Any malignancy | 6 (4.9) | 4 (5.4) | 1.11 (.30, 4.09) | .87 |
Metastatic solid tumor | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .91 |
Mild liver disease | 2 (1.6) | 3 (4.1) | 2.56 (.42, 15.67) | .29 |
Moderate–severe liver disease | 0 (0.0) | 1 (1.4) | … | |
AIDS | 1 (0.8) | 0 (0.0) | … | |
Median CWIC (25th, 75th) | 0 (0, 2) | 1.5 (0, 3) | … | .001 |
Hypertension | 82 (66.7) | 56 (75.7) | 1.56 (.81, 2.98) | .18 |
Current tobacco smoker | 5 (4.1) | 6 (8.3) | 2.11 (.62, 7.18) | .22 |
Obesity | 78 (64.5) | 53 (71.6) | 1.39 (.74, 2.61) | .30 |
Morbid obesity | 29 (24.6) | 19 (25.7) | 1.06 (.54, 2.07) | .86 |
Home medications | ||||
Either ACEIs or ARBs | 40 (32.5) | 27 (36.5) | 1.19 (.65, 2.18) | .57 |
Steroids | 6 (4.9) | 3 (4.1) | .82 (.20, 3.40) | .79 |
History of sick contact | 44 (37.0) | 16 (22.5) | .5 (.3, .9) | .03 |
Typical symptoms | ||||
Fever | 72 (58.5) | 44 (62.0) | 1.15 (.63, 2.10) | .63 |
Sore throat | 18 (14.6) | 2 (2.9) | .17 (.04, .78) | .01 |
Headache | 13 (10.6) | 4 (5.8) | .52 (.16, 1.67) | .264 |
Rhinorrhea | 7 (5.7) | 2 (2.9) | .50 (.10, 2.45) | .38 |
Shortness of breath | 83 (67.5) | 57 (80.3) | 1.96 (.98, 3.94) | .055 |
Cough | 96 (78.0) | 45 (64.3) | .51 (.27, .97) | .038 |
Hemoptysis | 1 (0.8) | 1 (1.4) | 1.77 (.11, 28.71) | .69 |
Fatigue | 41 (33.3) | 21 (30.0) | .86 (.46, 1.62) | .63 |
Myalgia | 29 (23.8) | 16 (22.9) | .95 (.47, 1.91) | .89 |
Nausea, vomiting | 23 (18.7) | 9 (12.9) | .64 (.28, 1.48) | .29 |
Diarrhea | 32 (26.0) | 13 (18.3) | .64 (.31, 1.32) | .22 |
Abdominal pain | 11 (8.9) | 2 (2.9) | .30 (.06, 1.39) | .11 |
Altered mental status | 18 (14.6) | 21 (28.4) | 2.31 (1.14, 4.71) | .02 |
Vital signs on admission | ||||
Supplemental oxygen required on hospitalization | 33 (26.8) | 44 (59.5) | 4.0 (2.17, 7.38) | <.0001 |
Vital signs within first 24 hours | ||||
Temperature | 74 (60.2) | 52 (70.3) | 1.57 (.85, 2.90) | .15 |
Abnormal chest X-ray on admission | 84 (68.9) | 66 (90.4) | 4.27 (1.79, 10.16) | .001 |
Laboratory findings on admission | ||||
Leukopenia | 14 (11.4) | 7 (9.5) | .81 (.31, 2.12) | .67 |
Lymphocytopenia | 62 (50.8) | 44 (60.3) | 1.47 (.82, 2.64) | .20 |
Thrombocytopenia | 22 (17.9) | 15 (20.3) | 1.17 (.56, 2.42) | .68 |
Elevated alanine aminotransferase | 43 (36.1) | 24 (34.3) | .92 (.50, 1.71) | .79 |
Elevated aspartate aminotransferase | 67 (59.3) | 46 (70.8) | 1.66 (.87, 3.19) | .13 |
Elevated C-reactive protein | 105 (93.8) | 63 (98.4) | 4.20 (.51, 34.94) | .15 |
Elevated procalcitonin | 84 (77.8) | 60 (93.8) | 4.29 (1.41, 12.99) | .006 |
Elevated creatinine | 45 (37.2) | 38 (56.7) | 2.21 (1.21, 4.06) | .01 |
Characteristics | Nonsevere (n = 123) (%) | Severe (n = 74) (%) | OR (95% CI) | P |
---|---|---|---|---|
Age group | ||||
<60 years | 65 (52.8) | 28 (37.8) | 1.8 (1.02, 3.3) | .04 |
>60 years | 58 (47.2) | 46 (62.2) | … | |
Sex | ||||
Male | 58 (47.2) | 45 (60.8) | 0.6 (.3, 1.03) | .06 |
Female | 65 (52.8) | 29 (39.2) | … | |
Race | ||||
White | 19 (15.8) | 15 (21.4) | 0.7 (.3, 1.5) | .38 |
Black | 101 (84.2) | 55 (78.6) | … | |
Comorbidities | ||||
At least 1 comorbidity | 97 (80.8) | 64 (91.4) | 2.32 (.95, 5.69) | .061 |
Myocardial infarction | 5 (4.1) | 4 (5.4) | 1.34 (.35, 5.19) | .663 |
Congestive heart failure | 10 (8.1) | 10 (13.5) | 1.76 (.70, 4.47) | .226 |
Peripheral vascular disease | 0 (0.0) | 5 (6.8) | … | |
Cerebrovascular disease | 9 (7.3) | 8 10.8) | 1.53 (.57, 4.17) | .398 |
Dementia | 16 (13.0) | 5 (6.8) | .49 (.17, 1.38) | .169 |
Chronic pulmonary disease | 18 (14.6) | 20 (27.0) | 2.16 (1.06, 4.42) | .03 |
Connective tissue disease | 0 (0.0) | 2 (2.7) | … | |
Peptic ulcer disease | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .90 |
Diabetes | 37 (30.1) | 36 (48.6) | 2.20 (1.21, 4.0) | .009 |
Hemiplegia | 5 (4.1) | 4 (5.4) | 1.35 (.35, 5.19) | .66 |
Renal disease | 12 (9.8) | 22 (29.7) | 3.91 (1.80, 8.51) | <.0001 |
Any malignancy | 6 (4.9) | 4 (5.4) | 1.11 (.30, 4.09) | .87 |
Metastatic solid tumor | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .91 |
Mild liver disease | 2 (1.6) | 3 (4.1) | 2.56 (.42, 15.67) | .29 |
Moderate–severe liver disease | 0 (0.0) | 1 (1.4) | … | |
AIDS | 1 (0.8) | 0 (0.0) | … | |
Median CWIC (25th, 75th) | 0 (0, 2) | 1.5 (0, 3) | … | .001 |
Hypertension | 82 (66.7) | 56 (75.7) | 1.56 (.81, 2.98) | .18 |
Current tobacco smoker | 5 (4.1) | 6 (8.3) | 2.11 (.62, 7.18) | .22 |
Obesity | 78 (64.5) | 53 (71.6) | 1.39 (.74, 2.61) | .30 |
Morbid obesity | 29 (24.6) | 19 (25.7) | 1.06 (.54, 2.07) | .86 |
Home medications | ||||
Either ACEIs or ARBs | 40 (32.5) | 27 (36.5) | 1.19 (.65, 2.18) | .57 |
Steroids | 6 (4.9) | 3 (4.1) | .82 (.20, 3.40) | .79 |
History of sick contact | 44 (37.0) | 16 (22.5) | .5 (.3, .9) | .03 |
Typical symptoms | ||||
Fever | 72 (58.5) | 44 (62.0) | 1.15 (.63, 2.10) | .63 |
Sore throat | 18 (14.6) | 2 (2.9) | .17 (.04, .78) | .01 |
Headache | 13 (10.6) | 4 (5.8) | .52 (.16, 1.67) | .264 |
Rhinorrhea | 7 (5.7) | 2 (2.9) | .50 (.10, 2.45) | .38 |
Shortness of breath | 83 (67.5) | 57 (80.3) | 1.96 (.98, 3.94) | .055 |
Cough | 96 (78.0) | 45 (64.3) | .51 (.27, .97) | .038 |
Hemoptysis | 1 (0.8) | 1 (1.4) | 1.77 (.11, 28.71) | .69 |
Fatigue | 41 (33.3) | 21 (30.0) | .86 (.46, 1.62) | .63 |
Myalgia | 29 (23.8) | 16 (22.9) | .95 (.47, 1.91) | .89 |
Nausea, vomiting | 23 (18.7) | 9 (12.9) | .64 (.28, 1.48) | .29 |
Diarrhea | 32 (26.0) | 13 (18.3) | .64 (.31, 1.32) | .22 |
Abdominal pain | 11 (8.9) | 2 (2.9) | .30 (.06, 1.39) | .11 |
Altered mental status | 18 (14.6) | 21 (28.4) | 2.31 (1.14, 4.71) | .02 |
Vital signs on admission | ||||
Supplemental oxygen required on hospitalization | 33 (26.8) | 44 (59.5) | 4.0 (2.17, 7.38) | <.0001 |
Vital signs within first 24 hours | ||||
Temperature | 74 (60.2) | 52 (70.3) | 1.57 (.85, 2.90) | .15 |
Abnormal chest X-ray on admission | 84 (68.9) | 66 (90.4) | 4.27 (1.79, 10.16) | .001 |
Laboratory findings on admission | ||||
Leukopenia | 14 (11.4) | 7 (9.5) | .81 (.31, 2.12) | .67 |
Lymphocytopenia | 62 (50.8) | 44 (60.3) | 1.47 (.82, 2.64) | .20 |
Thrombocytopenia | 22 (17.9) | 15 (20.3) | 1.17 (.56, 2.42) | .68 |
Elevated alanine aminotransferase | 43 (36.1) | 24 (34.3) | .92 (.50, 1.71) | .79 |
Elevated aspartate aminotransferase | 67 (59.3) | 46 (70.8) | 1.66 (.87, 3.19) | .13 |
Elevated C-reactive protein | 105 (93.8) | 63 (98.4) | 4.20 (.51, 34.94) | .15 |
Elevated procalcitonin | 84 (77.8) | 60 (93.8) | 4.29 (1.41, 12.99) | .006 |
Elevated creatinine | 45 (37.2) | 38 (56.7) | 2.21 (1.21, 4.06) | .01 |
Data are presented as n (%) unless otherwise indicated.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; COVID-19, coronavirus disease 2019; CWIC, Charlson Weighted Index of Comorbidity; OR, odds ratio.
Table 1.
Univariate Analysis of Predictors for Severe COVID-19 Infection
Characteristics | Nonsevere (n = 123) (%) | Severe (n = 74) (%) | OR (95% CI) | P |
---|---|---|---|---|
Age group | ||||
<60 years | 65 (52.8) | 28 (37.8) | 1.8 (1.02, 3.3) | .04 |
>60 years | 58 (47.2) | 46 (62.2) | … | |
Sex | ||||
Male | 58 (47.2) | 45 (60.8) | 0.6 (.3, 1.03) | .06 |
Female | 65 (52.8) | 29 (39.2) | … | |
Race | ||||
White | 19 (15.8) | 15 (21.4) | 0.7 (.3, 1.5) | .38 |
Black | 101 (84.2) | 55 (78.6) | … | |
Comorbidities | ||||
At least 1 comorbidity | 97 (80.8) | 64 (91.4) | 2.32 (.95, 5.69) | .061 |
Myocardial infarction | 5 (4.1) | 4 (5.4) | 1.34 (.35, 5.19) | .663 |
Congestive heart failure | 10 (8.1) | 10 (13.5) | 1.76 (.70, 4.47) | .226 |
Peripheral vascular disease | 0 (0.0) | 5 (6.8) | … | |
Cerebrovascular disease | 9 (7.3) | 8 10.8) | 1.53 (.57, 4.17) | .398 |
Dementia | 16 (13.0) | 5 (6.8) | .49 (.17, 1.38) | .169 |
Chronic pulmonary disease | 18 (14.6) | 20 (27.0) | 2.16 (1.06, 4.42) | .03 |
Connective tissue disease | 0 (0.0) | 2 (2.7) | … | |
Peptic ulcer disease | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .90 |
Diabetes | 37 (30.1) | 36 (48.6) | 2.20 (1.21, 4.0) | .009 |
Hemiplegia | 5 (4.1) | 4 (5.4) | 1.35 (.35, 5.19) | .66 |
Renal disease | 12 (9.8) | 22 (29.7) | 3.91 (1.80, 8.51) | <.0001 |
Any malignancy | 6 (4.9) | 4 (5.4) | 1.11 (.30, 4.09) | .87 |
Metastatic solid tumor | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .91 |
Mild liver disease | 2 (1.6) | 3 (4.1) | 2.56 (.42, 15.67) | .29 |
Moderate–severe liver disease | 0 (0.0) | 1 (1.4) | … | |
AIDS | 1 (0.8) | 0 (0.0) | … | |
Median CWIC (25th, 75th) | 0 (0, 2) | 1.5 (0, 3) | … | .001 |
Hypertension | 82 (66.7) | 56 (75.7) | 1.56 (.81, 2.98) | .18 |
Current tobacco smoker | 5 (4.1) | 6 (8.3) | 2.11 (.62, 7.18) | .22 |
Obesity | 78 (64.5) | 53 (71.6) | 1.39 (.74, 2.61) | .30 |
Morbid obesity | 29 (24.6) | 19 (25.7) | 1.06 (.54, 2.07) | .86 |
Home medications | ||||
Either ACEIs or ARBs | 40 (32.5) | 27 (36.5) | 1.19 (.65, 2.18) | .57 |
Steroids | 6 (4.9) | 3 (4.1) | .82 (.20, 3.40) | .79 |
History of sick contact | 44 (37.0) | 16 (22.5) | .5 (.3, .9) | .03 |
Typical symptoms | ||||
Fever | 72 (58.5) | 44 (62.0) | 1.15 (.63, 2.10) | .63 |
Sore throat | 18 (14.6) | 2 (2.9) | .17 (.04, .78) | .01 |
Headache | 13 (10.6) | 4 (5.8) | .52 (.16, 1.67) | .264 |
Rhinorrhea | 7 (5.7) | 2 (2.9) | .50 (.10, 2.45) | .38 |
Shortness of breath | 83 (67.5) | 57 (80.3) | 1.96 (.98, 3.94) | .055 |
Cough | 96 (78.0) | 45 (64.3) | .51 (.27, .97) | .038 |
Hemoptysis | 1 (0.8) | 1 (1.4) | 1.77 (.11, 28.71) | .69 |
Fatigue | 41 (33.3) | 21 (30.0) | .86 (.46, 1.62) | .63 |
Myalgia | 29 (23.8) | 16 (22.9) | .95 (.47, 1.91) | .89 |
Nausea, vomiting | 23 (18.7) | 9 (12.9) | .64 (.28, 1.48) | .29 |
Diarrhea | 32 (26.0) | 13 (18.3) | .64 (.31, 1.32) | .22 |
Abdominal pain | 11 (8.9) | 2 (2.9) | .30 (.06, 1.39) | .11 |
Altered mental status | 18 (14.6) | 21 (28.4) | 2.31 (1.14, 4.71) | .02 |
Vital signs on admission | ||||
Supplemental oxygen required on hospitalization | 33 (26.8) | 44 (59.5) | 4.0 (2.17, 7.38) | <.0001 |
Vital signs within first 24 hours | ||||
Temperature | 74 (60.2) | 52 (70.3) | 1.57 (.85, 2.90) | .15 |
Abnormal chest X-ray on admission | 84 (68.9) | 66 (90.4) | 4.27 (1.79, 10.16) | .001 |
Laboratory findings on admission | ||||
Leukopenia | 14 (11.4) | 7 (9.5) | .81 (.31, 2.12) | .67 |
Lymphocytopenia | 62 (50.8) | 44 (60.3) | 1.47 (.82, 2.64) | .20 |
Thrombocytopenia | 22 (17.9) | 15 (20.3) | 1.17 (.56, 2.42) | .68 |
Elevated alanine aminotransferase | 43 (36.1) | 24 (34.3) | .92 (.50, 1.71) | .79 |
Elevated aspartate aminotransferase | 67 (59.3) | 46 (70.8) | 1.66 (.87, 3.19) | .13 |
Elevated C-reactive protein | 105 (93.8) | 63 (98.4) | 4.20 (.51, 34.94) | .15 |
Elevated procalcitonin | 84 (77.8) | 60 (93.8) | 4.29 (1.41, 12.99) | .006 |
Elevated creatinine | 45 (37.2) | 38 (56.7) | 2.21 (1.21, 4.06) | .01 |
Characteristics | Nonsevere (n = 123) (%) | Severe (n = 74) (%) | OR (95% CI) | P |
---|---|---|---|---|
Age group | ||||
<60 years | 65 (52.8) | 28 (37.8) | 1.8 (1.02, 3.3) | .04 |
>60 years | 58 (47.2) | 46 (62.2) | … | |
Sex | ||||
Male | 58 (47.2) | 45 (60.8) | 0.6 (.3, 1.03) | .06 |
Female | 65 (52.8) | 29 (39.2) | … | |
Race | ||||
White | 19 (15.8) | 15 (21.4) | 0.7 (.3, 1.5) | .38 |
Black | 101 (84.2) | 55 (78.6) | … | |
Comorbidities | ||||
At least 1 comorbidity | 97 (80.8) | 64 (91.4) | 2.32 (.95, 5.69) | .061 |
Myocardial infarction | 5 (4.1) | 4 (5.4) | 1.34 (.35, 5.19) | .663 |
Congestive heart failure | 10 (8.1) | 10 (13.5) | 1.76 (.70, 4.47) | .226 |
Peripheral vascular disease | 0 (0.0) | 5 (6.8) | … | |
Cerebrovascular disease | 9 (7.3) | 8 10.8) | 1.53 (.57, 4.17) | .398 |
Dementia | 16 (13.0) | 5 (6.8) | .49 (.17, 1.38) | .169 |
Chronic pulmonary disease | 18 (14.6) | 20 (27.0) | 2.16 (1.06, 4.42) | .03 |
Connective tissue disease | 0 (0.0) | 2 (2.7) | … | |
Peptic ulcer disease | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .90 |
Diabetes | 37 (30.1) | 36 (48.6) | 2.20 (1.21, 4.0) | .009 |
Hemiplegia | 5 (4.1) | 4 (5.4) | 1.35 (.35, 5.19) | .66 |
Renal disease | 12 (9.8) | 22 (29.7) | 3.91 (1.80, 8.51) | <.0001 |
Any malignancy | 6 (4.9) | 4 (5.4) | 1.11 (.30, 4.09) | .87 |
Metastatic solid tumor | 3 (2.4) | 2 (2.7) | 1.11 (.18, 6.81) | .91 |
Mild liver disease | 2 (1.6) | 3 (4.1) | 2.56 (.42, 15.67) | .29 |
Moderate–severe liver disease | 0 (0.0) | 1 (1.4) | … | |
AIDS | 1 (0.8) | 0 (0.0) | … | |
Median CWIC (25th, 75th) | 0 (0, 2) | 1.5 (0, 3) | … | .001 |
Hypertension | 82 (66.7) | 56 (75.7) | 1.56 (.81, 2.98) | .18 |
Current tobacco smoker | 5 (4.1) | 6 (8.3) | 2.11 (.62, 7.18) | .22 |
Obesity | 78 (64.5) | 53 (71.6) | 1.39 (.74, 2.61) | .30 |
Morbid obesity | 29 (24.6) | 19 (25.7) | 1.06 (.54, 2.07) | .86 |
Home medications | ||||
Either ACEIs or ARBs | 40 (32.5) | 27 (36.5) | 1.19 (.65, 2.18) | .57 |
Steroids | 6 (4.9) | 3 (4.1) | .82 (.20, 3.40) | .79 |
History of sick contact | 44 (37.0) | 16 (22.5) | .5 (.3, .9) | .03 |
Typical symptoms | ||||
Fever | 72 (58.5) | 44 (62.0) | 1.15 (.63, 2.10) | .63 |
Sore throat | 18 (14.6) | 2 (2.9) | .17 (.04, .78) | .01 |
Headache | 13 (10.6) | 4 (5.8) | .52 (.16, 1.67) | .264 |
Rhinorrhea | 7 (5.7) | 2 (2.9) | .50 (.10, 2.45) | .38 |
Shortness of breath | 83 (67.5) | 57 (80.3) | 1.96 (.98, 3.94) | .055 |
Cough | 96 (78.0) | 45 (64.3) | .51 (.27, .97) | .038 |
Hemoptysis | 1 (0.8) | 1 (1.4) | 1.77 (.11, 28.71) | .69 |
Fatigue | 41 (33.3) | 21 (30.0) | .86 (.46, 1.62) | .63 |
Myalgia | 29 (23.8) | 16 (22.9) | .95 (.47, 1.91) | .89 |
Nausea, vomiting | 23 (18.7) | 9 (12.9) | .64 (.28, 1.48) | .29 |
Diarrhea | 32 (26.0) | 13 (18.3) | .64 (.31, 1.32) | .22 |
Abdominal pain | 11 (8.9) | 2 (2.9) | .30 (.06, 1.39) | .11 |
Altered mental status | 18 (14.6) | 21 (28.4) | 2.31 (1.14, 4.71) | .02 |
Vital signs on admission | ||||
Supplemental oxygen required on hospitalization | 33 (26.8) | 44 (59.5) | 4.0 (2.17, 7.38) | <.0001 |
Vital signs within first 24 hours | ||||
Temperature | 74 (60.2) | 52 (70.3) | 1.57 (.85, 2.90) | .15 |
Abnormal chest X-ray on admission | 84 (68.9) | 66 (90.4) | 4.27 (1.79, 10.16) | .001 |
Laboratory findings on admission | ||||
Leukopenia | 14 (11.4) | 7 (9.5) | .81 (.31, 2.12) | .67 |
Lymphocytopenia | 62 (50.8) | 44 (60.3) | 1.47 (.82, 2.64) | .20 |
Thrombocytopenia | 22 (17.9) | 15 (20.3) | 1.17 (.56, 2.42) | .68 |
Elevated alanine aminotransferase | 43 (36.1) | 24 (34.3) | .92 (.50, 1.71) | .79 |
Elevated aspartate aminotransferase | 67 (59.3) | 46 (70.8) | 1.66 (.87, 3.19) | .13 |
Elevated C-reactive protein | 105 (93.8) | 63 (98.4) | 4.20 (.51, 34.94) | .15 |
Elevated procalcitonin | 84 (77.8) | 60 (93.8) | 4.29 (1.41, 12.99) | .006 |
Elevated creatinine | 45 (37.2) | 38 (56.7) | 2.21 (1.21, 4.06) | .01 |
Data are presented as n (%) unless otherwise indicated.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; COVID-19, coronavirus disease 2019; CWIC, Charlson Weighted Index of Comorbidity; OR, odds ratio.
Discussion
Unlike SARS-CoV and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has become a pandemic. While little has been reported regarding the predictors for severe COVID-19 infection, much is known regarding the risk factors and predictors for mortality [11, 25]. In our study we report pre-existing renal disease, supplemental oxygen requirement at admission, acute renal insufficiency, and CRP values on admission as independent predictors of severe COVID-19 infections.
The kidneys play a key role in immune hemostasis. Reduced renal function delays the clearance of circulating cytokines, leading to a persistent inflammatory state [26]. Renal dysfunction causes reduced lymphocyte numbers and function, creating an immunodeficient state, predisposing to severe infections [27]. Patients with renal disease often have the additional comorbidities of either diabetes or hypertension; yet interestingly, neither diabetes nor hypertension emerged as predictors of COVID-19 disease severity in the multivariable logistic regression analysis. Perhaps renal disease represents those patients with poorer control of either diabetes or hypertension (leading to the development of chronic kidney disease) and this explains why the latter 2 conditions fell out in multivariable analysis; well-controlled diabetes and hypertension may not portend the same risk as chronically uncontrolled disease. Some patients also had end-stage renal disease, which is a state of immune dysregulation in which buildup of uremic toxins and cytokines activates innate immune cells leading to a vicious cycle of further cytokine release and reactive oxygen species production [26]. Patients with kidney disease may also have received different antihypertensive or antihyperglycemic medications than those who did not have chronic kidney disease; we did not evaluate this specific potential in our study.
It is also interesting that acute renal insufficiency (whether in patients with chronic kidney disease or normal baseline renal function) was associated with adverse outcome. SARS-CoV-2 is strongly suspected to use ACE2 as its receptor, and ACE2 binding affinity has been shown to be one of the most important determinants of SARS-CoV infectivity [28]. Perhaps acute renal insufficiency reflects more efficient binding of SARS-CoV-2 to ACE2 given the location of ACE2 expression. Interestingly, ACE inhibitors and ARBs increase ACE2 expression, yet our analysis did not detect an association between ACE inhibitor or ARB use, or hypertension or diabetes, and disease severity. Persons taking ACE inhibitors or ARBs at home but presenting with renal insufficiency generally have those medications held upon admission. While SARS-CoV-2 enters cells by binding to ACE2, ACE2 also reduces inflammation [19]. If one hypothesizes that ACE2 expression decreases inflammation, and that withholding drugs that increase its expression was done mainly in patients with acute renal insufficiency, perhaps a proinflammatory reaction to drug withdrawal could contribute to an unfavorable outcome in such patients.
The need for supplemental oxygen for baseline hypoxia was an independent factor for severe disease in our study. A recently published study showed that oxygen saturation below 90% despite oxygen supplementation was a powerful predictor for a fatal outcome [29]. Given that ACE2 is expressed in lung epithelium, hypoxia may represent more avid binding to SARS-CoV-2 in those hosts. Interestingly, ACE2 is also expressed by endothelial cells, which represent one-third of lung cells [30]. The endothelium functions to promote vasodilation, fibrinolysis, and anti-aggregation; thus, endothelial damage may lead to a hypercoagulable state [31]. Accumulation of coagulation factors in lungs can drive ARDS through activation of protease-activated receptors. Microvascular permeability from endothelial injury can also facilitate viral invasion [31]. Thus, the direct effect of viral invasion and indirect effects through endothelial damage lead to severe hypoxia.
CRP level upon admission was also associated with severe infection. Every 1-unit increase in CRP increased the risk of severe disease by 0.06%. CRP is a homopentameric acute-phase inflammatory protein. Baseline CRP values are influenced by age, gender, smoking status, weight, lipid levels, and blood pressure, and by genetics [32]. Recent studies have reported that cases of severe COVID-19 exhibit increased plasma levels of interleukin (IL) 2, IL-6, IL-7, IL-10, granulocyte colony-stimulating factor (GCSF), tumor necrosis factor ɑ (TNF-ɑ), and others [33]. IL-6 is the main inducer of CRP gene expression, with IL-1 and TNF-ɑ also playing a role [32]. Elevated CRP may reflect severe disease as an indirect marker of elevated IL-6 and TNF-ɑ. CRP not only reflects inflammation, it also enhances the immune response. CRP can be irreversibly dissociated into monomeric subunits termed monomeric or modified CRP (mCRP) at either high concentrations of urea or elevated temperatures in the absence of calcium, and mCRP promotes monocyte chemotaxis and recruitment of circulating leukocytes to areas of inflammation. Modified CRP also binds immunoglobulin G (IgG) Fc receptors in an interaction leading to release of proinflammatory cytokines [32]. Thus, elevated CRP at admission may both reflect significant inflammation and itself drive further inflammation. And given that elevated levels of urea promote formation of mCRP, it fits that acute and chronic kidney disease may be associated with adverse outcomes.
Table 2.
Multivariate Logistic Regression Analysis of Predictors for Severe COVID-19 Infection
Variables | OR (95% CI) | P |
---|---|---|
Pre-existing renal disease | 7.4 (2.5, 22.0) | <.0001 |
Oxygen required on admission | 2.9 (1.3, 6.7) | .01 |
Elevated creatinine from baseline | 2.7 (1.3, 5.6) | .01 |
Initial CRP value | 1.006 (1.001, 1.01) | .02 |
Variables | OR (95% CI) | P |
---|---|---|
Pre-existing renal disease | 7.4 (2.5, 22.0) | <.0001 |
Oxygen required on admission | 2.9 (1.3, 6.7) | .01 |
Elevated creatinine from baseline | 2.7 (1.3, 5.6) | .01 |
Initial CRP value | 1.006 (1.001, 1.01) | .02 |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; OR, odds ratio.
Table 2.
Multivariate Logistic Regression Analysis of Predictors for Severe COVID-19 Infection
Variables | OR (95% CI) | P |
---|---|---|
Pre-existing renal disease | 7.4 (2.5, 22.0) | <.0001 |
Oxygen required on admission | 2.9 (1.3, 6.7) | .01 |
Elevated creatinine from baseline | 2.7 (1.3, 5.6) | .01 |
Initial CRP value | 1.006 (1.001, 1.01) | .02 |
Variables | OR (95% CI) | P |
---|---|---|
Pre-existing renal disease | 7.4 (2.5, 22.0) | <.0001 |
Oxygen required on admission | 2.9 (1.3, 6.7) | .01 |
Elevated creatinine from baseline | 2.7 (1.3, 5.6) | .01 |
Initial CRP value | 1.006 (1.001, 1.01) | .02 |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; OR, odds ratio.
In our data, having contact with a sick person was associated with a lower risk of severe disease. Perhaps some of those patients with contact with a sick person knew they were at risk of exposure and therefore were already attempting to minimize that risk through hand hygiene, masks, physical isolation, or using separate bathrooms, thus decreasing the potential amount of virus to which they were exposed. This would, however, only account for patients where someone else was symptomatic or exposed soon enough for the patient to be able to take precautions. Patients with known contact with a sick person may also have presented sooner due to a heightened suspicion of having contracted COVID-19, and thus received care more rapidly [34]. Recall bias may also have contributed. One other potential explanation is that the sickest patients were more confused or were intubated rapidly and therefore could not provide a history of contact with someone who was sick, which would have impacted the recording of a such contact in the EMR and thus our results.
Patients over 60 years old were significantly more likely to have severe infection. In multivariable analysis, however, age was not found to be an independent predicting factor for severe infection. This may reflect that the occurrence of kidney disease tends to be higher in older people and kidney disease was the stronger predictor in the model. Older age has been significantly associated with death in previous studies [35, 36]. This might be related to less robust immune responses, as older age has been linked with declined immune competence [37]. On the contrary, older macaques had a stronger host innate immune responses to viral infection after inoculation with SARS-CoV than the younger macaques due to differential expression of proinflammatory genes [38]. This proinflammatory state along with age-dependent functional deficits in T-cell and B-cell response could lead to poor outcomes [39]. This proinflammatory state is expressed by elevation in CRP. Elderly infected patients could be at risk of acute renal injury manifesting in elevation in serum creatinine on hospital admission. A study by Wang et al from China showed that patients admitted to the ICU were older and had a greater number of comorbid conditions, including a significant elevation in creatinine on admission, than those not admitted to the ICU [13]. Thus, age in our studied cohort might have been a confounding factor with regard to elevated serum creatinine and CRP.
During the COVID-19 pandemic, racial and ethnic minorities, especially blacks, have been reported to be severely or disproportionately impacted. Our study did not show a disparity in severity by race, so we also investigated the relationship by ADI (as a proxy for socioeconomic status). No association was found between ADI and severity or between race and severity after controlling for ADI.
Our study has several limitations. This was a single-institution study among all the admitted patients, which makes generalizability of the findings difficult. Because of the retrospective nature of the study design, all variables in the studied patients were not available. Therefore, the role of some of these variables in predicting severity of the infection could have been underestimated. Last, the small sample size of our study and a predominantly black and overweight/obese cohort could have limited the generalizability of interpretation for some of the findings (for, eg, race). Nonetheless, our study did involve a population of black patients in the Detroit area and can provide valuable information on which factors are the most significant predictors of severe disease in that population.
Conclusions
Our study identifies the presence of renal disease and elevated creatinine and CRP on hospital admission and requirement for supplemental oxygen at the time of hospitalization as independent predictors for severe COVID-19 infection. Early identification of these risk factors can result in aggressive supportive care and prompt treatment intervention. Subsequent research involving multiple study sites and with a larger database can further validate the findings of our study and help in early clinical decision making.
Note
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
References
Lu
R
,
Zhao
X
,
Li
J
, et al.
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
.
Lancet
2020
;
395
:
565
–
74
.
World Health Organization
.
Home page
. Available at: https://www.who.int. Accessed 20 April 2020.
Hoehl
S
,
Rabenau
H
,
Berger
A
, et al.
Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China
.
N Engl J Med
2020
;
382
:
1278
–
80
.
Hu
Z
,
Song
C
,
Xu
C
, et al.
Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China
.
Sci China Life Sci
2020
;
63
:
706
–
11
.
Wang
Y
,
Liu
Y
,
Liu
L
,
Wang
X
,
Luo
N
,
Ling
L
.
Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-coronavirus-2 in Shenzhen, China
.
J Infect Dis
2020
; 11:1770–4.
Bai
Y
,
Yao
L
,
Wei
T
, et al.
Presumed asymptomatic carrier transmission of COVID-19
.
JAMA
2020
;
323
:
1406
–
7
.
Kimball
A
,
Hatfield
KM
,
Arons
M
, et al. ;
Public Health—Seattle & King County; CDC COVID-19 Investigation Team
.
Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020
.
MMWR Morb Mortal Wkly Rep
2020
;
69
:
377
–
81
.
Roxby
AC
,
Greninger
AL
,
Hatfield
KM
, et al.
Detection of SARS-CoV-2 among residents and staff members of an independent and assisted living community for older adults—Seattle, Washington, 2020
.
MMWR Morb Mortal Wkly Rep
2020
;
69
:
416
–
8
.
Wu
Z
,
McGoogan
JM
.
Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention
.
JAMA
2020
;
323
:
1239
–
42
.
Guan
WJ
,
Ni
ZY
,
Hu
Y
, et al.
Clinical characteristics of coronavirus disease 2019 in China
.
N Engl J Med
2020
;
382
:
1708
–
20
.
Wang
D
,
Hu
B
,
Hu
C
, et al.
Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
.
JAMA
2020
;
323
:
1061
–
9
.
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020
.
MMWR Morb Mortal Wkly Rep
2020
;
69
:
343
–
6
.
Arentz
M
,
Yim
E
,
Klaff
L
, et al.
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
.
JAMA
2020
;
323
:
1612
–
14
.
Zhou
F
,
Yu
T
,
Du
R
, et al.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
.
Lancet
2020
;
395
:
1054
–
62
.
Zhonghua Liu Xing Bing Xue Za Zhi. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020; 41(2):145–51. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12-March 28, 2020
.
MMWR Morb Mortal Wkly Rep
2020
;
69(13)
:
382
–
6
.
Fang
L
,
Karakiulakis
G
,
Roth
M
.
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lancet Respir Med
2020
;
8
:
e21
.
Charlson
ME
,
Pompei
P
,
Ales
KL
,
MacKenzie
CR
.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
.
J Chronic Dis
1987
;
40
:
373
–
83
.
Khwaja
A
.
KDIGO clinical practice guidelines for acute kidney injury
.
Nephron Clin Pract
2012
;
120
:
c179
–
84
.
Knighton
AJ
,
Savitz
L
,
Belnap
T
,
Stephenson
B
,
VanDerslice
J
.
Introduction of an area deprivation index measuring patient socioeconomic status in an integrated health system: implications for population health
.
EGEMS
2016
;
4
:
1238
.
Grasselli
G
,
Zangrillo
A
,
Zanella
A
, et al.
Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy
.
JAMA
2020
;
323
:
1574
–
81
.
Tecklenborg
J
,
Clayton
D
,
Siebert
S
,
Coley
SM
.
The role of the immune system in kidney disease
.
Clin Exp Immunol
2018
;
192
:
142
–
50
.
Kato
S
,
Chmielewski
M
,
Honda
H
, et al.
Aspects of immune dysfunction in end-stage renal disease
.
Clin J Am Soc Nephrol
2008
;
3
:
1526
–
33
.
Wan
Y
,
Shang
J
,
Graham
R
,
Baric
RS
,
Li
F
.
Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus
.
J Virol
2020
;
94
.
Jiang Xie
M
,
Naima
C
,
Zhengyang
F
, et al.
Association between hypoxemia and mortality in patients with COVID-19
.
Mayo Clin Proc 2020; 95:1138–47. doi:10.1016/j.mayocp.2020.04.006
.
Yuki
K
,
Fujiogi
M
,
Koutsogiannaki
S
.
COVID-19 pathophysiology: a review
.
Clin Immunol
2020
;
215
:
108427
.
Whyte
CS
,
Morrow
GB
,
Mitchell
JL
,
Chowdary
P
,
Mutch
NJ
.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19
.
J Thromb Haemost
2020
. doi:10.1111/jth.14872
Sproston
NR
,
Ashworth
JJ
.
Role of C-reactive protein at sites of inflammation and infection
.
Front Immunol
2018
;
9
:
754
.
Xiong
Y
,
Liu
Y
,
Cao
L
, et al.
Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
.
Emerg Microbes Infect
2020
;
9
:
761
–
70
.
Pongpirul
WA
,
Pongpirul
K
,
Ratnarathon
AC
,
Prasithsirikul
W
.
Journey of a Thai taxi driver and novel coronavirus
.
N Engl J Med
2020
;
382
:
1067
–
8
.
Wu
C
,
Chen
X
,
Cai
Y
, et al.
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China
.
JAMA Intern Med
2020
. doi:10.1001/jamainternmed.2020.0994
Yang
X
,
Yu
Y
,
Xu
J
, et al.
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
.
Lancet Respir Med
2020
. doi:10.1016/S2213-2600(20)30079-5
Goronzy
JJ
,
Fang
F
,
Cavanagh
MM
,
Qi
Q
,
Weyand
CM
.
Naive T cell maintenance and function in human aging
.
J Immunol
2015
;
194
:
4073
–
80
.
Smits
SL
,
de Lang
A
,
van den Brand
JM
, et al.
Exacerbated innate host response to SARS-CoV in aged non-human primates
.
PLoS Pathog
2010
;
6
:
e1000756
.
Opal
SM
,
Girard
TD
,
Ely
EW
.
The immunopathogenesis of sepsis in elderly patients
.
Clin Infect Dis
2005
;
41(
Suppl 7)
:
S504
–
12
.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Topic:
I agree to the terms and conditions. You must accept the terms and conditions.
Submit a comment
Name
Affiliations
Comment title
Comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Citations
Views
Altmetric
Metrics
Total Views 9,711
7,305 Pageviews
2,406 PDF Downloads
Since 5/1/2020
Month: | Total Views: |
---|---|
May 2020 | 23 |
June 2020 | 249 |
July 2020 | 466 |
August 2020 | 582 |
September 2020 | 451 |
October 2020 | 395 |
November 2020 | 949 |
December 2020 | 275 |
January 2021 | 347 |
February 2021 | 347 |
March 2021 | 344 |
April 2021 | 294 |
May 2021 | 290 |
June 2021 | 248 |
July 2021 | 242 |
August 2021 | 249 |
September 2021 | 241 |
October 2021 | 216 |
November 2021 | 209 |
December 2021 | 177 |
January 2022 | 178 |
February 2022 | 124 |
March 2022 | 193 |
April 2022 | 163 |
May 2022 | 192 |
June 2022 | 166 |
July 2022 | 128 |
August 2022 | 96 |
September 2022 | 130 |
October 2022 | 148 |
November 2022 | 90 |
December 2022 | 115 |
January 2023 | 100 |
February 2023 | 83 |
March 2023 | 71 |
April 2023 | 101 |
May 2023 | 71 |
June 2023 | 75 |
July 2023 | 53 |
August 2023 | 86 |
September 2023 | 58 |
October 2023 | 35 |
November 2023 | 53 |
December 2023 | 81 |
January 2024 | 88 |
February 2024 | 69 |
March 2024 | 74 |
April 2024 | 62 |
May 2024 | 50 |
June 2024 | 42 |
July 2024 | 48 |
August 2024 | 59 |
September 2024 | 35 |
Citations
122 Web of Science
×
Email alerts
Related articles in PubMed
Citing articles via
More from Oxford Academic